Correction: Impact of bictegravir/emtricitabine/tenofovir alafenamide on health-related quality of life and economic outcomes in HIV care: Substudy of the BIC-NOW clinical trial
Sergio Sequera-Arquelladas, María J. Vivancos, David Vinuesa, Antonio Collado, Ignacio De Los Santos, Patricia Sorni, Noemi Cabello-Clotet, Marta Montero, Carlos Ramos Font, Alberto Terron, Maria José Galindo, Onofre Martinez, Pablo Ryan, Mohamed Omar-Mohamed
Abstract
Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.
Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsHIV-related health complications and treatments · HIV/AIDS drug development and treatment · HIV/AIDS Research and Interventions
Notice of Republication
This article was republished on on January 8, 2026 to remove confidential information. Please download this article again to view the correct version.
The reference list from the paper itself. Each links out to its DOI / PubMed record.
- 1Sequera-Arquelladas S, Vivancos MJ, Vinuesa D, Collado A, Santos IDL, Sorni P, et al. Impact of bictegravir/emtricitabine/tenofovir alafenamide on health-related quality of life and economic outcomes in HIV care: Substudy of the BIC-NOW clinical trial. P Lo S One. 2025;20(9):e 0323167. doi: 10.1371/journal.pone.0323167 40982450 PMC 12453196 · doi ↗ · pubmed ↗